Virata (90mg) 20 Tablets

Ticagrelor is a unique antiplatelet medication that works through different mechanisms compared to aspirin and clopidogrel. Similar to clopidogrel, ticagrelor selectively inhibits the binding of adenosine diphosphate (ADP) to the platelet P2Y12 receptor. Unlike clopidogrel, however, ticagrelor acts as an orally active, reversible inhibitor of the platelet P2Y12 receptor. By binding to the receptor and reversibly inhibiting ADP binding and platelet aggregation, ticagrelor leads to the inhibition of platelet aggregation and vasodilation. Through these pharmacological actions, ticagrelor is effective in preventing thrombotic cardiovascular events such as myocardial infarction, stroke, and thrombosis of peripheral arteries. It is prescribed to patients with acute coronary syndrome (ACS) and those who have undergone percutaneous coronary intervention (PCI). Additionally, it is used for the prevention of stent thrombosis in cases where stents are inserted into the coronary arteries.

Antiplatelet

Unveiling its multifaceted uses and transformative applications as follows:

• Ticagrelor 90mg tablets are used to reduce the chances of stroke or heart attack.
• It is also used to prevent the occurrence of atherothrombotic events in patients with acute coronary syndrome (ACS) or myocardial infarction (MI).
• This includes the treatment of symptomatic myocardial infarction (AMI) and stroke.
• It reduces the risk of unexpected death in patients with acute coronary syndrome (ACS) or myocardial infarction (MI).
• Ticagrelor 90mg tablets help to keep blood flowing smoothly in the body, ensuring that the brain, heart, and other parts of the body receive adequate blood flow to function properly.

Tailoring Treatment for Optimal Health, Prescribed Medication Dosage is:

• Myocardial infarction (MI), stroke, or acute coronary syndrome (ACS)-
• For the first year of treatment after an MI or non-ST-elevation ACS (NSTE-ACS), 90 mg once a day for the first 30 days, followed by 60 mg once a day.
• For the reduction of thrombotic cardiovascular events in patients with ACS or NSTE-ACS, 90 mg once a day for the first 21 days, followed by 60 mg once a day.
• Peripheral arterial disease (PAD)-
• 90 mg once a day for the first 21 days, followed by 60 mg once a day.

Ticagrelor is a prescription medication prescribed to treat certain heart conditions. It is important to follow your doctor's instructions and not exceed the recommended dosage.In case of an overdose, it is vital to seek immediate medical attention. The specific treatment will depend on the individual's overall health and the amount of medication consumed. It may include supportive care, such as monitoring vital signs and managing any symptoms. Dialysis, certain medications, or gastrointestinal lavage may also be used.

If you miss a dose of Ticagrelor, it is important to take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue on your regular schedule. Do not take a double dose to make up for a missed dose. It is also important to note that you should not take any additional medication to make up for the missed dose. If you have any questions about dosing, it is always best to consult with your doctor or pharmacist for guidance. They may provide you with the best advice based on your overall health, any other medications you take, and the directions of your prescription.

Before taking Ticagrelor, it is crucial to read the patient information leaflet that comes with the medication, as it contains extensive information about the drug, including how to take it and any potential side effects. If you have any further questions, consulting your doctor or pharmacist is advisable. Here are some basic steps regarding Ticagrelor's use:

Discerning instances where this medication may not be appropriate:

• Severe Bruising or Bleeding

• Recent Stroke or Transient Ischemic Attack (TIA)

• Active Pathological Bleeding

• Lack of Kidney Function

• Recent Myocardial Infarction (MI)

• Pregnancy and Lactation

Unraveling the side effects lurking behind this medications are as follows:

• Abdominal pain
• Gastritis
• Nasopharyngitis
• Upper respiratory tract infection
• Back pain
• Muscular pain
• Bone fracture
• Pain in extremities
• Bruising
• Bleeding
• Nosebleed
• Abnormal liver function
• Kidney failure
• Hypertension
• Irregular heartbeat
• Heart attack
• Stroke
• Amnesia

The warnings and precautions for Ticagrelor include several critical considerations. It is not recommended for patients with a history of myocardial infarction for over a year, coronary artery disease, type 2 diabetes mellitus, or a prior ischemic stroke. Caution is advised in patients with a propensity to bleed, including those with recent trauma or surgery, coagulation disorders, or active/recent gastrointestinal bleeding, as well as those at increased risk of trauma. Ticagrelor should not be used in individuals without a pacemaker who have sick sinus syndrome, second or third-degree AV block, or bradycardic-related syncope. Other considerations include asthma and/or chronic obstructive pulmonary disease, hyperuricemia or gouty arthritis, central sleep apnea including Cheyne-Stokes respiration, and thrombotic thrombocytopenic purpura. Regular renal function checks are recommended one month after starting treatment. It is crucial to discontinue the medication five days before any elective surgery if antiplatelet effects are not desired. Premature discontinuation of treatment should be avoided. Ticagrelor is not recommended for co-administration with high maintenance doses of acetylsalicylic acid greater than 300 mg or with NSAIDs, oral anticoagulants, and fibrinolytics within 24 hours, as well as antifibrinolytic therapy or recombinant factor VIIa, and medicinal products that induce bradycardia or angiotensin receptor blockers. The medication may impair the ability to drive or operate machinery. It is contraindicated in individuals with moderate hepatic impairment, moderate to severe renal impairment, and is not recommended for children under 18 years of age or for elderly individuals aged 75 years and older. Additionally, it is advised that women of childbearing potential use effective contraception during therapy, and the medication is not recommended during pregnancy or lactation. Lastly, the 90 mg dose is not recommended for patients with an NIHSS score greater than 5 who are receiving thrombolysis.

The drug interactions with ticagrelor include:

• CYP3A4 Inhibitors (e.g., ketoconazole) – Can increase ticagrelor levels, increasing the risk of bleeding.
• CYP3A4 Inducers (e.g., rifampin) – Can decrease ticagrelor levels, reducing its effectiveness.
• Other Antiplatelet Agents (e.g., clopidogrel) – May increase the risk of bleeding.

The food interactions that should be considered while using Ticagrelor are:

• No significant interactions with food.
• Taking with food may help enhance absorption.

Ticagrelor is a prescription medication that reduces the risk of heart attack or stroke in patients with coronary artery disease or peripheral artery disease. It is essential to follow the manufacturer's or your physician's storage instructions to ensure the medication remains effective and safe to use. Ticagrelor tablets should be stored at room temperature, in a range between 77°F (25°C) and 86°F (30°C). Heat, direct sunlight, and moisture can degrade the medication, so it should be kept in a dry, cool place away from windows and bathrooms. Ensure to keep the medication secure and out of the reach of children or pets. The original container is the best storage place until the medication is used, and always follow physician or pharmacist instructions for storage. Would you like help with anything else?